|
Table 1: Demographic, comorbidity clinical, pharmacological, and biochemical characteristics of the study population. (N = 21). |
|
|
Characteristics |
n (%) |
|
Demographics |
|
|
Age [years] |
58 (49.5-59) |
|
Gender |
|
|
Male |
18 (85.7) |
|
Female |
3 (14.3) |
|
Etiology |
|
|
Ischaemic cardiomyopathy |
16 (76.2) |
|
Chronic heart failure |
5 (23.8) |
|
Cardiac valve disease |
2 (9.5) |
|
Pulmonary arterial hypertension |
1 (4.8) |
|
Congenital heart disease |
1 (4.8) |
|
Comorbidities |
|
|
Dyslipidemia |
8 (38.1) |
|
Obesity |
14 (66.7) |
|
Type 2 diabetes mellitus |
6 (28.6) |
|
Systemic arterial hypertension |
12 (57.1) |
|
Smoking |
8 (38.1) |
|
Clinical |
|
|
BMI [kg/m2] |
28.6 (26.4-29.7) |
|
LVEF [%] |
55 (38-62) |
|
Functional class |
|
|
1 |
17 (81.0) |
|
2 |
3 (14.3) |
|
3 |
1 (4.8) |
|
IscT |
4 (19.0) |
|
ArrT |
1 (4.8) |
|
Pharmacological |
|
|
ACEI |
10 (47.6) |
|
ARA |
4 (19.0) |
|
AAP |
18 (85.7) |
|
Estatinas |
18 (85.7) |
|
BB |
14 (66.7) |
|
CA |
4 (19.0) |
|
Diuréticos |
5 (23.8) |
|
Biochemical, (mg/dL)* |
|
|
Glucose |
99 [61.5-135.2] |
|
C-HDL |
29.3 [21.7-36.2] |
|
C-LDL |
72 [30.7-121.7] |
|
Triglycerides |
156 [50.2-233] |
|
AAP = antiplatelet agents. ACEI = angiotensin converting enzyme inhibitor. ARA = angiotensin receptor antagonist. ArrT = arrhythmical threshold. BB = beta-blockers. BMI = body mass index. CA = calcium antagonists. IscT = ischaemic threshold. LVEF = left ventricular ejection fraction. * Data are presented in means [p25-p75] |
|